These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37215127)

  • 1. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
    Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
    Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer.
    Tai Q; Shao H; Liu Y; Li E; Zhao R
    J BUON; 2019; 24(5):2006-2012. PubMed ID: 31786868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 5. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
    Ma J; Yao S; Li XS; Kang HR; Yao FF; Du N
    Medicine (Baltimore); 2015 Oct; 94(42):e1489. PubMed ID: 26496252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The short-term efficacy of neoadjuvant SOX versus SOX plus immune checkpoint inhibitor following laparoscopic gastrectomy for locally advanced gastric cancer: a multicenter retrospective cohort study in China.
    Cui H; Yang Y; Song L; Yuan Z; Sun L; Du J; Lu Y; Ning N; Cui J; Shi Y; Chen L; Wei B
    Cancer Immunol Immunother; 2024 Sep; 73(11):216. PubMed ID: 39235478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
    Iwatsuki M; Orita H; Kobayashi K; Hidaka S; Arigami T; Kusumoto T; Satake H; Oki E; Tsutsumi S; Tobimatsu K; Shimokawa M; Saeki H; Makiyama A; Baba H; Mori M
    Gastric Cancer; 2022 Jan; 25(1):180-187. PubMed ID: 34379229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction].
    Li YJ; Yuan P; Zhai JN; Yao YF; Tan LX; Li ZW; Zhang XY; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul; 27(7):684-693. PubMed ID: 39004983
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety and efficacy of laparoscopic gastrectomy for patients with locally advanced gastric cancer following neoadjuvant chemotherapy.
    Liu L; Wang C; Li F; Zhang X; Cheng X; Lin S; Liu Y; Yang C; Li W
    Sci Rep; 2022 Jun; 12(1):10384. PubMed ID: 35726012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Neoadjuvant Chemotherapy for Advanced Gastric Cancer in Elderly Patients.
    Mukoyama T; Kanaji S; Sawada R; Harada H; Urakawa N; Goto H; Hasegawa H; Yamashita K; Matsuda T; Oshikiri T; Kakeji Y
    Anticancer Res; 2023 Dec; 43(12):5649-5656. PubMed ID: 38030165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study.
    Shi JW; Zhou Y; Wu S
    Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10472-10480. PubMed ID: 37975371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
    Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis.
    Zhong H; Liu X; Tian Y; Cao S; Li Z; Liu G; Sun Y; Zhang X; Han Z; Meng C; Jia Z; Wang Q; Zhou Y
    Surg Endosc; 2023 Aug; 37(8):5902-5915. PubMed ID: 37072637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.
    Sah BK; Zhang B; Zhang H; Li J; Yuan F; Ma T; Shi M; Xu W; Zhu Z; Liu W; Yan C; Li C; Liu B; Yan M; Zhu Z
    Nat Commun; 2020 Nov; 11(1):6093. PubMed ID: 33257672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
    Wang T; Li C; Li X; Zhai J; Wang S; Shen L
    Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients.
    Ota M; Saeki H; Uehara H; Matsuda Y; Tsutsumi S; Kusumoto T; Yasui H; Ubukata Y; Yamaguchi S; Orita H; Izawa N; Kakizoe S; Shimokawa M; Yoshizumi T; Kakeji Y; Mori M; Oki E
    Int J Clin Oncol; 2023 Sep; 28(9):1166-1175. PubMed ID: 37368093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.